HC Wainwright Weighs in on Acurx Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:ACXP)

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Equities researchers at HC Wainwright upped their Q3 2024 earnings estimates for Acurx Pharmaceuticals in a report issued on Monday, August 12th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of ($0.23) for the quarter, up from their prior forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.64) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.24) EPS, FY2026 earnings at ($3.20) EPS, FY2027 earnings at ($3.61) EPS and FY2028 earnings at ($3.81) EPS.

Acurx Pharmaceuticals Trading Up 7.3 %

Shares of NASDAQ ACXP opened at $2.04 on Wednesday. The firm has a market capitalization of $32.32 million, a PE ratio of -1.73 and a beta of -1.72. Acurx Pharmaceuticals has a one year low of $1.17 and a one year high of $8.82. The business has a 50-day moving average price of $2.22 and a two-hundred day moving average price of $2.40.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. During the same period last year, the company posted ($0.28) EPS.

Institutional Trading of Acurx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ACXP. Sigma Planning Corp acquired a new stake in shares of Acurx Pharmaceuticals in the fourth quarter worth about $38,000. Prospect Financial Services LLC acquired a new position in shares of Acurx Pharmaceuticals during the 4th quarter valued at about $977,000. Finally, NBC Securities Inc. acquired a new stake in Acurx Pharmaceuticals in the 1st quarter worth approximately $34,000. 11.53% of the stock is owned by institutional investors.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.